The PCCTC

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
@ucsdhealth.bsky.social #ProstateCancer #PCSM
www.onclive.com/view/consens...

Such an honor and so much fun to join the Cancer Clear and Simple @uwhealth.bsky.social Carbone Cancer Center Podcast to discuss liquid biopsies in cancer!

cancer.wisc.edu/community-ou...

Consensus Recommendations for PARP Inhibitor Use in Metastatic Prostate Cancer - Michael Carducci Alan Bryce is joined by Michael Carducci to discuss consensus recommendations from the US Prostate Cancer Consensus Conference regarding PARP inhibitor testing and treatment strategies. Dr. Carducci e...

PCCTC investigator Michael A. Carducci, MD discusses consensus recommendations for PARP inhibitor use in metastatic prostate cancer with Alan Bryce, MD via UroToday: www.urotoday.com/video-lectur...

Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field ...

Esteemed PCCTC investigator Dr Rana McKay discusses the exciting developments in biomarker-driven therapy for metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/emergin...

Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss!

Register now: surveys.mayoclinic.org/jfe/form/SV_...

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic...

PCCTC investigator Dr Rana McKay and colleagues discuss personalizing treatment intensification in metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/persona...

Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial - Prostate Cancer and Prostatic Diseases Prostate Cancer and Prostatic Diseases - Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial

Just published: Analysis from the TRANSFORMER prostate cancer study reveals baseline testosterone could be considered in the treatment selection process when bipolar androgen therapy is an option www.nature.com/articles/s41...

Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies Radium-223 (Ra-223) has been approved since 2013 for men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Since then…

From PCCTC investigator Dr Rana McKay and colleagues, "Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies," published in Eur Urol Oncol www.sciencedirect.com/science/arti...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer Intensified by Androgen-Receptor Pathway Inhibitors: A Multinational Real-World Analysis of the PCCTC-managed IRONMAN Registry www.urotoday.com/conference-h...

Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent

#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”

PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!

Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!

#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...

The PCCTC at #ASCO25 via UroToday: A Randomized, Open-Label, Phase 2b Study of the Bromodomain Inhibitor ZEN-3694 + Enzalutamide vs Enzalutamide in Patients with mCRPC www.urotoday.com/conference-h...

Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343

Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343

Mark Your Calendar! 📆 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss!

Register now: surveys.mayoclinic.org/jfe/form/SV_...

DOD prostate cancer research program FY25 funding opportunities - The Cancer Letter The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research. To access this subscriber-only content please log in or subscribe.If your institution […]

DOD prostate cancer research program FY25 funding opportunities
https://cancerletter.com/funding-opportunities/20250523_10a/

The Prostate Cancer Clinical Trials Consortium at ASCO 2025: Abstracts Listing

#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!

The PCCTC at ASCO25: Oral Abstract Sessions 3 June | Hall D1 | Live Stream #5002: Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.. Presenter: Michael Ong, MD, BSc, FRCPC (The Ottawa Hospital Cancer Centre) 10:33 AM – 10:45 AM CDT #5007: A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis. Presenter: Rana R. McKay, MD, FASCO (University of California San Diego) 11:57 AM – 12:09 PM CDT

The PCCTC at ASCO25: Rapid Oral Abstract Sessions 1 June | Hall D2 | Live Stream #5014: Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion. Presenter: Eric Huttenlocher Bent, MD, PhD (MSK) 4:42 PM – 4:48 PM CDT #5015: DB‑1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC). Presenter: Andrew Ohyama Parsonson, FRACP, MBBS (Macquarie University) 5:00 PM – 5:06 PM CDT #5017: Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC). Presenter: Capucine Baldini, MD, PhD (Institut Gustave Roussy) 5:12 PM – 5:18 PM CDT

The PCCTC at ASCO25: Poster Sessions Gupta S, et al. Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study. Abstract # 5043, Poster Bd # 242. Von Amsberg G, et al. Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC). Abstract # 5059, Poster Bd #258. Marulanda Corzo V, et al. PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes. Abstract # 5070, Poster Bd # 269. Bryce A, et al. Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Abstract # 5071, Poster Bd # 270. Attwell M, et al. A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC). Abstract # TPS5123, Poster Bd # 315b. Wise D, et al. Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC). Abstract # 5067, Poster Bd #266. Johnson G, et al. SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer. Abstract # TPS5125, Poster Bd # 316b.

The PCCTC at ASCO25: Publication Only Abstracts Sokolova A, et al. Barriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC). Abstract # e17073. George D, et al. Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study. Abstract # e17076. Schweizer M, et al. Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC). Abstract # e17032. Alonso Gordoa T, et al. Mevrometostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. Abstract # e17029.

We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!

At MSK, there are exciting new therapies that are proving effective at treating metastatic prostate cancer.

In this 📹, Dr. Michael Morris, a genitourinary medical oncologist and the Prostate Cancer Section Head at MSK, speaks about one in particular.

Plus, read more here: bit.ly/4mfOKhg

Biden’s cancer renews debate about prostate screenings for older men It is not unusual for a man of Biden’s age to skip prostate cancer screening, for a variety of reasons.

The PCCTC's Dr. Michael J. Morris and other experts weigh in on President Biden's prostate cancer diagnosis and the debate about prostate screenings for older men: www.washingtonpost.com/health/2025/...

We’re headed to Lagos for the IRONMAN Conference from September 4–6, with a special pre-conference session on September 3. This isn’t just an event—it’s a major milestone in global health and cancer research you won’t want to miss!

Register now: surveys.mayoclinic.org/jfe/form/SV_...

Cover page of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...

Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons: In 2020, BLOODPAC recommended 11 pre-analytical minimal technical data elements for collection and submission of liquid biopsy data to public databases. This article expands on that work by recommending 22 clinical context and 10 patient context data elements. These elements, essential for liquid biopsy data submitted to repositories like the BLOODPAC Data Commons, cover tumor characteristics, disease progression, and patient demographics, supporting biomarker validation, research, and clinical trials.

Just Published: PCCTC leadership and colleagues release recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons (Clin Transl Sci): pmc.ncbi.nlm.nih.gov/articles/PMC...

🌍 Save the Date! We’re heading to Lagos for the IRONMAN Conference happening September 4–6, with a special pre-conference on September 3. This is more than an event, it’s a milestone you won’t want to miss!

Register today: surveys.mayoclinic.org/jfe/form/SV_...

Genitourinary medical oncologist Howard Scher, MD, is serving as chairperson for a session on diagnostic and predictive biomarkers for cancer. @mskcancercenter.bsky.social @theaacr.bsky.social

Learn more: bit.ly/3Gwdvpe

Howard Scher, MD Head, Biomarker Development Program Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College I am most honored to be the 2025 recipient of the Urology Care Foundation (UCF) Richard D. Williams, MD Prostate Cancer Research Excellence Award, and for the Society of Urologic Oncology and UCF for recognizing the transformative effect of co-developing innovative therapeutics along with biomarkers to better inform medical decision making and improve patient outcomes. The successful execution of this strategy was made possible by the mission-driven, multidisciplinary, multi-center collaborations established by the Prostate Cancer Clinical Trials Consortium (PCCTC), a program enabled by the Prostate Cancer Foundation (PCF) and the Prostate Cancer Research Program (PCRP) of the US Department of Defense (DOD), that I had the privilege to lead which to date has provided over 16,200 patients access to clinical trials of potentially breakthrough therapies, including those for patients with disease for which no life-prolonging therapeutic options exist. I would like to thank Howard Soule from the PCF and Jake Vinson from the PCCTC in achieving these successes. I am humbled by this honor and would like to thank the prostate cancer research community, study participants, and many advocates who have made these advances possible.

Congratulations, Howard I. Scher, MD, recipient of the Urology Care Foundation's Richard D. Williams, MD Prostate Cancer Research Excellence Award!

Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) featured at the 2025 AACR Annual Meeting (Abstract 3630 and Abstract 4935)

#AACR25: Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) are featured at this year's AACR Annual Meeting www.aacr.org/meeting/aacr...